好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Efficacy of Brigatinib in patients with nervous system tumors: A Systematic Review and Meta-Analysis
Neuro-oncology
P3 - Poster Session 3 (11:45 AM-12:45 PM)
6-013
Carry out a meta-analysis to assess the efficacy and safety of Brigatinib regarding the treatment of nervous system tumors, especially related to tumoral response.

Brigatinib is a targeted cancer therapy that belongs to a class of drugs known as tyrosine kinase inhibitors, effective in the treatment of non-small cell lung cancer with a specific genetic alteration known as anaplastic lymphoma kinase fusion. However, there is still no consolidated evidence regarding the efficacy and safety of Brigatinib in treating central nervous system (CNS) tumors.
A comprehensive systematic review using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was conducted to evaluate the use of Brigatinib in patients with nervous system tumors. The search was conducted using the following databases: PubMed, Embase, and Cochrane. Statistical analysis was performed using R Studio software, version 4.3.1, and will include a comparison of the effects of Brigatinib on efficacy and safety. Study heterogeneity was assessed using the I² index.
Eleven interventional studies were included in the analysis, comprising 1016 patients. In these articles, the response rate with Brigatinib in patients with a nervous system tumor was 56.94% (95% CI 48.03 to 65.67%).
This study shows a moderate overall response rate across the included studies, with significant heterogeneity, suggesting considerable variability. Despite this, the response rates indicate Brigatinib's potential efficacy in treating CNS tumors.
Authors/Disclosures
Felipe A. Gouhie
PRESENTER 		Mr. Gouhie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Marjan Farma.
Caio L. Nazar Cunha Mr. Nazar Cunha has nothing to disclose.
Gabriel P. Carísio, Med school graduate student Mr. Carísio has nothing to disclose.
Ricardo R. Filho Mr. Filho has nothing to disclose.
João P. Alves Rodrigues, Student/Academic Mr. Alves Rodrigues has nothing to disclose.
Larissa Ferreira Machado, Estudante Mrs. Ferreira Machado has nothing to disclose.
Lucas Figueira Vieira Mr. Figueira Vieira has nothing to disclose.
Pedro R. Borges, Sr. Mr. Borges has nothing to disclose.
Victor Luiz B. Furlan Mr. Furlan has nothing to disclose.
Jose A. Neto Mr. Neto has nothing to disclose.
Hélio F. Queiroz, Jr. Mr. Queiroz has nothing to disclose.